ELAN CP PLC ADR (ELN) Upgraded by Zacks to NEUTRAL

Zacks Investment Research upgraded shares of ELAN CP PLC ADR (ELN) from UNDERPERFORM to NEUTRAL on August 28, 2012, with a target price of $12.00.

Elan Corporation, plc is a leading worldwide specialty pharmaceutical company focused on the discovery, development and marketing of therapeutic products and services in neurology, acute care and pain management and on the development and commercialization of products using its extensive range of proprietary drug delivery technologies. The company consists of three operating divisions: Elan Pharmaceuticals, Elan Pharmaceutical Technologies and Elan Pharmaceutical Operations.

Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.

To get a free copy of the research report on ELAN CP PLC ADR (ELN),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .